E-LIB Suche - Ergebnisse für: Mohty M

1

French early nationwide idecabtagene vicleucel chimeric ant..:

Ferment, B. ; Lambert, J. ; Caillot, D....
British Journal of Haematology. , 2024

Link: https://doi.org/10.1111/..

2

Allogeneic hematopoietic cell transplantation is equally ef..:

Sadowska-Klasa, A. ; Zaucha, J. M. ; Labopin, M....
Bone Marrow Transplantation. 59 (2024) 3 - p. 387-394 , 2024

Link: https://doi.org/10.1038/..

3

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSE..:

Nooka, A ; Lesokhin, A ; Mohty, M...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S405 , 2023

Link: https://doi.org/10.1016/..

4

CO52 Comparative Analysis of Tabelecleucel Versus Standard ..:

Brookhart, M.A. ; Barlev, A. ; Mohty, M....
Value in Health. 26 (2023) 12 - p. S23 , 2023

Link: https://doi.org/10.1016/..

5

PROGNOSTIC SCORING SYSTEMS FOR SEVERE CRS AND ICANS AFTER A..:

Sesques, P. ; Di blasi, R. ; Legouill, S....
Hematological Oncology. 41 (2023) S2 - p. 202-204 , 2023

Link: https://doi.org/10.1002/..

6

Transfusion needs after CD19 CAR T‐cells for large B‐cell l..:

Vic, S. ; Thibert, J. ; Bachy, E....
Hematological Oncology. 41 (2023) S2 - p. 534-536 , 2023

Link: https://doi.org/10.1002/..

7

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANT..:

Mohty, M ; Tomasson, M ; Arnulf, B...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S404-S405 , 2023

Link: https://doi.org/10.1016/..

8

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PA..:

Raje, N ; Leleu, X ; Lesokhin, A...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S406-S407 , 2023

Link: https://doi.org/10.1016/..

9

P529: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGIST..:

Platzbecker, U. ; Angelucci, E. ; Montesinos, P....
HemaSphere. 6 (2022) - p. 428-429 , 2022

Link: https://doi.org/10.1097/..

10

P1355: VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDRO..:

Mohty, M. ; Yakoub-Agha, I. ; Dalle, J.-H....
HemaSphere. 6 (2022) - p. 1240-1241 , 2022

Link: https://doi.org/10.1097/..

11

P1371: GRAFT-VERSUS-HOST DISEASE OFFERS NO GRAFT-VERSUS-LEU..:

Shimoni, A. ; Peczynski, C. ; Labopin, M....
HemaSphere. 6 (2022) - p. 1255-1256 , 2022

Link: https://doi.org/10.1097/..

12

The first steps towards a diverse and inclusive EBMT: a pos..:

Montoto, S. ; Snowden, J. A. ; Chabannon, C....
Bone Marrow Transplantation. 57 (2022) 3 - p. 343-346 , 2022

Link: https://doi.org/10.1038/..

13

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION A..:

Lesokhin, A. M. ; Arnulf, B. ; Niesvizky, R....
HemaSphere. 6 (2022) - p. 839-840 , 2022

Link: https://doi.org/10.1097/..

14

S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSU..:

Harbi, S. ; Boher, J.-M. ; Forcade, E....
HemaSphere. 6 (2022) - p. 137-138 , 2022

Link: https://doi.org/10.1097/..

15

S238: MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICA..:

Nagler, A. ; Labopin, M. ; Mielke, S....
HemaSphere. 6 (2022) - p. 139-140 , 2022

Link: https://doi.org/10.1097/..